Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

<p>Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases Post-transaction cash, cash equivalents and investments of approximately $218 million expected to fund operations through 2026, including key data readouts from the Phase 2b trial in TED and the Phase 2 […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/tourmaline-bio-announces-closing-of-merger-with-talaris-therapeutics-and-concurrent-private-placement-of-75-million/">Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>